Search results
Dec 5, 2023 · NEWS & MEDIA. Novavax's Updated COVID-19 Vaccine Now Authorized in Canada. December 5, 2023. Novavax's updated protein-based non-mRNA COVID-19 vaccine will be available in Canada for individuals aged 12 and older in the coming days.
- On This Page
- Who The Vaccine Is Indicated For
- Effectiveness
- Dosage
- Vaccine Ingredients
- Possible Side Effects
- Vaccine Review, Approval and Monitoring
- Related Links
The vaccine is authorized for use in people who are 12 years of age and older. The safety and effectiveness in people younger than 12 years of age have not yet been established for the vaccine. This vaccine is also authorized as a booster for people who are 18 years of age and older. The safety and effectiveness in people younger than 18 years of a...
Clinical trials showed that beginning 1 week after the second dose, Novavax Nuvaxovid®COVID-19 vaccine was: 1. 90% effective in protecting trial participants aged 18 and above against COVID-19 2. 80% effective in protecting trial participants aged 12 to 17 against COVID-19 A booster dose of the Novavax Nuvaxovid®COVID-19 vaccine was shown to increa...
Primary series
The dosing schedule authorized by Health Canada is to give 2 doses 21 days apart, based on evidence from clinical trials. One dose contains 5 micrograms of the SARS-CoV-2 spike protein (original strain) with 50 micrograms of Matrix-M adjuvant.
Booster dose
A booster dose (5 micrograms) of the Novavax Nuvaxovid®COVID-19 vaccine may be administered intramuscularly in individuals 18 years of age approximately 6 months after completing the second dose of the primary series. Your province or territory decides when people receive their doses of the vaccine. These decisions are based on public health recommendations and the latest evidence. 1. Find out how provinces and territories are making COVID-19 vaccine decisions
Medicinal ingredient
1. SARS-CoV-2 recombinant spike (rS) protein (original strain) 2. Matrix-M adjuvant 2.1. composed of 40 nanometer particles based on saponin extracted from the soap bark tree (Quillaja saponaria Molina) 2.2. helps stimulate an immune response to the vaccine
Other ingredients
Non-medicinal ingredients 1. disodium hydrogen phosphate heptahydrate 2. hydrochloric acid (for adjustment of pH) 3. polysorbate 80 4. sodium chloride 5. sodium dihydrogen phosphate monohydrate 6. sodium hydroxide (for adjustment of pH) 7. water for injection For adjuvant: 1. cholesterol 2. phosphatidylcholine 3. potassium chloride 4. potassium dihydrogen phosphate 5. disodium hydrogen phosphate dihydrate 6. sodium chloride
After getting vaccinated, it's common to have temporary side effects. These can last a few hours to a few daysafter vaccination. This is the body's natural response, as it's working hard to build protection against the disease.
Health Canada's independent drug review process is recognized around the world for its high standards and rigor. Our decisions are based only on scientific and medical evidence showing that vaccines are safe and effective. The benefits must outweigh any risks. The Novavax Nuvaxovid®COVID-19 vaccine was authorized for use in Canada under the Food an...
Dec 5, 2023 · Novavax's first vaccine to protect against COVID-19, known as Nuvaxovid, was authorized for use in Canadians 18 and over by Health Canada in February 2022. Pfizer-BioNTech and Moderna's mRNA...
Feb 17, 2022 · February 17, 2022 - Ottawa, ON - Health Canada. Today, Health Canada authorized Novavax's Nuvaxovid COVID-19 vaccine for the prevention of COVID-19 in adults 18 years of age and older. This is the fifth COVID-19 vaccine authorized in Canada.
Dec 5, 2023 · Tue, Dec 5, 2023, 4:01 PM 6 min read. In this article: NVAX. Novavax's updated protein-based non-mRNA COVID-19 vaccine will be available in Canada for individuals aged 12 and older in the...
Feb 17, 2022 · Novavax's COVID-19 vaccine has been approved for use in Canadians age 18 and older by Health Canada. The approval of the vaccine, known as Nuvaxovid, comes about 18 months after the federal...
